Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke(Harvard University), Mikaël J. Pittet(University of Geneva), Yoshiko Iwamoto(Harvard University), Vichnou Poirier-Colame(Inserm), Richard O. Hynes(Howard Hughes Medical Institute), Virna Cortez‐Retamozo(Vrije Universiteit Brussel), Gregory R. Wojtkiewicz(Harvard University), Ferdinando Pucci(Oregon Health & Science University), Ralph Weissleder(Massachusetts General Hospital), Takahiro Yamazaki(Inserm), Mari Mino–Kenudson(Massachusetts General Hospital), Laurence Zitvogel(Institut Gustave Roussy), Guido Kroemer(Institut Universitaire de France), Gordon J. Freeman(Dana-Farber Cancer Institute), Younes Redouane(Harvard University), Tiffany G. Huynh(Massachusetts General Hospital), Camilla Engblom(Karolinska Institutet), Steffen Rickelt(Allen Institute), Christopher Garris(Massachusetts General Hospital), Yi-Jang Lin(Harvard University), Andita Newton(Harvard University)
Cited by 954
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
A clearer vision for in vivo imaging
|Nature Biotechnology|2001|3.8k
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
|Cell Death and Differentiation|2008|3.3k
The molecular machinery of regulated cell death
|Cell Research|2019|2.5k
Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012
|Cell Death and Differentiation|2011|2.4k